Approval · Notice of Compliance 21189 · 2018
M-CLINDAMYCIN: Notice of Compliance 21189
Issued August 8, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 21189
- Date
- August 8, 2018
- Company
- Mantra Pharma Inc.Brossard, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Licensing agreement between two companies
- Canadian reference product
- DALACIN C (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| M-CLINDAMYCIN | 02479923 | Marketed |
| M-CLINDAMYCIN | 02479931 | Marketed |
Medicinal ingredients
- CLINDAMYCIN HCL 150 MG per CAP
- CLINDAMYCIN HCL 300 MG per CAP